| 引用本文: | 冯竹娥,赵丽,盛玉霞.齐拉西酮合并低剂量氟哌啶醇治疗精神分裂症顽固性幻听的临床疗效[J].中国现代应用药学,2016,33(2):216-219. |
| FENG Zhue,ZHAO Li,SHENG Yuxia.Clinical Efficacy of Ziprasidone Combined with Low Dose of Haloperidol in Treatment of Schizophrenia Auditory Hallucination Split[J].Chin J Mod Appl Pharm(中国现代应用药学),2016,33(2):216-219. |
|
| 摘要: |
| 目的 观察齐拉西酮合并低剂量氟哌啶醇治疗精神分裂症顽固性幻听症状的临床疗效和安全性，并探讨其作用机制。方法 符合纳入标准的60例患者随机分为观察组和对照组，每组30例，对照组单用抗精神病药齐拉西酮治疗，观察组以齐拉西酮合并低剂量氟哌啶醇进行治疗。于治疗前及治疗后2周末、4周末、8周末、12周末分别采用阳性和阴性症状量表(PANSS)、幻听量表(AHRS)治疗前后各次的减分率评定疗效，副反应量表(TESS)评定疗效及不良反应，疗程12周。结果 治疗前，观察组和对照组PANSS总分及各分量表得分、AHRS评分的组间差异均无显著性；治疗后，2组间PANSS总分及阴性量表评分、一般病理评分比较无显著性差异，但2组在阳性量表评分及AHRS评分的比较有显著性差异(P<0.01)。结论 齐拉西酮合并低剂量氟哌啶醇治疗精神分裂症顽固性幻听的效果充分显现，不良反应轻微，治疗依从性高，可作为临床治疗精神分裂症顽固性幻听的方法之一。 |
| 关键词: 顽固性幻听 药物疗法 齐拉西酮 氟哌啶醇 |
| DOI： |
| 分类号: |
| 基金项目:秦皇岛市科技计划项目(201401A195) |
|
| Clinical Efficacy of Ziprasidone Combined with Low Dose of Haloperidol in Treatment of Schizophrenia Auditory Hallucination Split |
|
FENG Zhue, ZHAO Li, SHENG Yuxia
|
|
Jiulong Mountain Hospital of Qinhuangdao City, Qinhuangdao 066000, China
|
| Abstract: |
| OBJECTIVE To observe the clinical efficacy and safety of division of ziprasidone combined with low dose of haloperidol in the treatment of mental disease refractory auditory hallucinations, and to explore its mechanism. METHODS In line with the inclusion criteria, 60 cases were randomly divided into observation group and control group, 30 cases in each group, control group were treated with single antipsychotic ziprasidone, and the observed group were treated with ziprasidone combined with low dose of haloperidol. Before treatment and after 2, 4, 8 and 12 weeks, positive and negative symptom table(PANSS), the reduction rate of auditory hallucinations scale(AHRS) before and after treatment were used to evaluate the efficacy, and treatment emergent symptom scale(TESS) were used to assess the efficacy and adverse reaction, with a treatment course of 12 weeks. RESULTS Before intervention, there were no significant difference in PANSS score and AHRS score between the observation group and the control group. After intervention there were no significant difference between the two groups in PANSS except positive symptom table, while there was significant difference between the two groups in AHRS. CONCLUSION Ziprasidone combined with low dose of haloperidol in the treatment of mental division disease refractory auditory hallucination effect fully displayed, help with minor side effects, compliance of treatment, disease refractory auditory hallucination of one way as the spirit of the clinical treatment of split. |
| Key words: auditory hallucination drug therapy ziprasidone haloperidol |
